ZA200508954B - Modified and stabilized BMP-11 propeptides and uses thereof - Google Patents

Modified and stabilized BMP-11 propeptides and uses thereof Download PDF

Info

Publication number
ZA200508954B
ZA200508954B ZA200508954A ZA200508954A ZA200508954B ZA 200508954 B ZA200508954 B ZA 200508954B ZA 200508954 A ZA200508954 A ZA 200508954A ZA 200508954 A ZA200508954 A ZA 200508954A ZA 200508954 B ZA200508954 B ZA 200508954B
Authority
ZA
South Africa
Prior art keywords
propeptide
gdf
bmp
modified
modified bmp
Prior art date
Application number
ZA200508954A
Other languages
English (en)
Inventor
Neil M Wolfman
Soo P Khor
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200508954B publication Critical patent/ZA200508954B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200508954A 2001-02-08 2002-02-08 Modified and stabilized BMP-11 propeptides and uses thereof ZA200508954B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26750901P 2001-02-08 2001-02-08

Publications (1)

Publication Number Publication Date
ZA200508954B true ZA200508954B (en) 2006-07-26

Family

ID=23019083

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200508954A ZA200508954B (en) 2001-02-08 2002-02-08 Modified and stabilized BMP-11 propeptides and uses thereof
ZA200306064A ZA200306064B (en) 2001-02-08 2003-08-06 Modified and stabalized GDF propeptides and uses thereof.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200306064A ZA200306064B (en) 2001-02-08 2003-08-06 Modified and stabalized GDF propeptides and uses thereof.

Country Status (23)

Country Link
US (6) US7202210B2 (pt)
EP (1) EP1397492B1 (pt)
JP (3) JP4280071B2 (pt)
AR (1) AR032567A1 (pt)
AT (1) ATE357519T1 (pt)
AU (1) AU2002243852B2 (pt)
BR (1) BR0207110A (pt)
CA (2) CA2437218A1 (pt)
CL (1) CL2009000648A1 (pt)
CY (1) CY1106629T1 (pt)
DE (1) DE60219006T2 (pt)
DK (1) DK1397492T3 (pt)
ES (1) ES2284828T3 (pt)
HK (1) HK1062457A1 (pt)
MX (1) MXPA03007063A (pt)
NO (1) NO333427B1 (pt)
NZ (2) NZ550297A (pt)
PL (2) PL212078B1 (pt)
PT (1) PT1397492E (pt)
SG (2) SG165982A1 (pt)
TW (2) TW200526779A (pt)
WO (1) WO2002068650A2 (pt)
ZA (2) ZA200508954B (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
KR20040096592A (ko) * 2002-02-21 2004-11-16 와이어쓰 폴리스타틴 도메인을 포함하는 단백질
MXPA04008150A (es) 2002-02-21 2005-06-17 Wyeth Corp Gasp1: una proteina que contiene dominio de folistatina.
US20040138118A1 (en) * 2002-09-16 2004-07-15 Neil Wolfman Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2004083432A1 (en) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
CA2526669A1 (en) * 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
EP2332977B1 (en) * 2004-07-23 2015-11-25 Acceleron Pharma Inc. ActRII receptor polypeptides
WO2006020884A2 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
MX2007011400A (es) * 2005-03-23 2007-10-11 Wyeth Corp Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
US20060240488A1 (en) * 2005-03-23 2006-10-26 Nowak John A Detection of an immune response to GDF-8 modulating agents
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
EP2502628B1 (en) * 2006-06-23 2016-12-14 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
CA2660523C (en) 2006-08-11 2019-03-19 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
EP2446896A1 (en) * 2006-12-18 2012-05-02 Acceleron Pharma, Inc. Activin-ActRII Antagonists for use in Increasing Red Blood Cells, increasing reticulocyte levels, or promoting erythropoiesis
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
RU2473362C2 (ru) * 2007-02-01 2013-01-27 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TWI548647B (zh) * 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EA025371B1 (ru) * 2007-02-09 2016-12-30 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
CN101790385A (zh) * 2007-07-12 2010-07-28 普罗森那技术公司 用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子
AU2008273096B2 (en) * 2007-07-12 2013-05-02 Academisch Ziekenhuis Leiden Molecules for targeting compounds to various selected organs or tissues
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
BRPI0811317A2 (pt) 2007-08-03 2015-01-27 Summit Corp Plc Combinação, embalagem farmcêutica, kit ou mbalagem par apaciente, agente auxiliar, compsoto, usos de um agente auxiliar e de um composto, e, processo para a produção de uma combinação
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
EP2614827B1 (en) 2007-10-26 2017-06-28 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
JP2011510678A (ja) * 2008-02-08 2011-04-07 プロセンサ ホールディング ビーブイ Dna反復不安定性関連遺伝性障害を治療するための方法及び手段
US9119818B2 (en) 2008-05-14 2015-09-01 Agriculture Victoria Services Pty Ltd Use of angiogenin or angiogenin agonists for treating diseases and disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP3363453A1 (en) * 2008-06-26 2018-08-22 Acceleron Pharma Inc. Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders
LT3494986T (lt) 2008-08-14 2020-07-10 Acceleron Pharma Inc. Gdf gaudyklės
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
MX336869B (es) 2008-11-03 2016-02-04 Alethia Biotherapeutics Inc Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
WO2010083034A1 (en) * 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
EP2421971B1 (en) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
KR20190090049A (ko) 2009-06-12 2019-07-31 악셀레론 파마 인코포레이티드 절두된 ActRIIB-FC 융합 단백질
IN2012DN02766A (pt) * 2009-09-09 2015-09-18 Acceleron Pharma Inc
JP5836961B2 (ja) * 2009-11-03 2015-12-24 アクセルロン ファーマ, インコーポレイテッド 脂肪肝疾患を処置するための方法
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
ES2616561T3 (es) 2009-12-24 2017-06-13 Biomarin Technologies B.V. Molécula para tratar un trastorno inflamatorio
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
US20120121576A1 (en) 2010-11-08 2012-05-17 Jasbir Seehra Actriia binding agents and uses thereof
KR101993259B1 (ko) 2011-03-31 2019-06-27 에이디씨 테라퓨틱스 에스에이 신장 결합 항원 1에 대한 항체 및 이의 항원 결합 단편
SG11201401220SA (en) 2011-10-21 2014-07-30 Pfizer Addition of iron to improve cell culture
DK2802351T3 (da) 2012-01-09 2019-05-13 Adc Therapeutics Sa Midler til behandling af triple-negativ brystkræft
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
WO2014000042A1 (en) * 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
CA2880649C (en) 2012-08-01 2023-03-14 Elizabeth MCNALLY Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
WO2014062535A1 (en) 2012-10-15 2014-04-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
NZ747350A (en) 2012-10-24 2020-07-31 Celgene Corp Methods for treating anemia
CN113604550A (zh) * 2012-10-24 2021-11-05 细胞基因公司 用于治疗贫血症的生物标志物
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6143270B2 (ja) * 2013-01-31 2017-06-07 学校法人東京薬科大学 マイオスタチン阻害ペプチド
JP2016518357A (ja) 2013-04-08 2016-06-23 プレジデント アンド フェローズ オブ ハーバード カレッジ 骨格筋幹細胞を若返らせる方法および組成物
US20160220640A1 (en) * 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
PT3027642T (pt) * 2013-07-31 2020-10-30 Amgen Inc Construtos do fator 15 de diferenciação de crescimento (gdf-15)
CN104725513A (zh) * 2013-12-20 2015-06-24 中国科学院上海生命科学研究院 融合蛋白及其在治疗多发性硬化中的用途
AU2015274277B2 (en) 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
CN106573966B (zh) 2014-07-30 2022-03-01 Ngm生物制药有限公司 用于治疗代谢异常的组合物和方法
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MD20170035A2 (ro) 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
DK3227675T3 (da) 2014-12-03 2023-05-30 Celgene Corp Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
JP6948331B2 (ja) 2016-01-06 2021-10-13 プレジデント アンド フェローズ オブ ハーバード カレッジ Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
TWI815793B (zh) 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
NZ210699A (en) 1984-01-04 1989-06-28 Int Genetic Eng Isolation of an osteogenic protein of the p3 immunologically related family
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
CA1341617C (en) 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
UA39161C2 (uk) 1984-07-06 2001-06-15 Новартіс Аг Рекомбінантний білок gm-csf для збільшення продукції гранулоцитів і макрофагів у пацієнтів, вектор і кднк, що його кодують
ATE128715T1 (de) 1984-07-16 1995-10-15 Celtrix Pharma Polypeptide induzierende faktoren in knochen und knorpel.
US4740587A (en) 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
NZ231899A (en) 1985-10-03 1991-07-26 Genentech Inc Human or porcine inhibin peptide compositions and dna encoding them
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US5215893A (en) 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4737578A (en) 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5187076A (en) 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
AU645244B2 (en) 1988-04-08 1994-01-13 Genetics Institute, Llc Bone and cartilage inductive compositions
US5071834A (en) 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
ATE162223T1 (de) 1989-03-28 1998-01-15 Genetics Inst Osteoinduktive zusammensetzungen
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
CA2020729A1 (en) 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5166190A (en) 1990-01-08 1992-11-24 Genentech, Inc. Method for increasing fertility in males
JPH06500991A (ja) 1990-05-16 1994-01-27 ジェネティックス・インスティテュート・インコーポレイテッド 骨および軟骨誘導蛋白質
EP0550625B1 (en) 1990-09-26 2003-11-05 Genetics Institute, LLC Bmp-5 derivatives
AU651421B2 (en) 1990-11-30 1994-07-21 Celtrix Pharmaceuticals, Inc. Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
AU662155B2 (en) 1991-05-10 1995-08-24 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
ATE175441T1 (de) 1991-06-25 1999-01-15 Genetics Inst Bmp-9 zusammensetzungen
AU661854B2 (en) * 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5171579A (en) 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
ATE242639T1 (de) 1992-07-31 2003-06-15 Curis Inc Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
DK1378572T3 (da) 1993-05-12 2007-02-05 Genetics Inst Llc BMP-11-sammensætninger
WO1995005846A1 (en) 1993-08-26 1995-03-02 Genetics Institute, Inc. Neural regeneration using human bone morphogenetic proteins
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
ATE305036T1 (de) 1994-07-08 2005-10-15 Univ Johns Hopkins Med Wachstums-differenzierungsfaktor-11
US5466190A (en) * 1994-07-25 1995-11-14 Deere & Company Precleaner for a cleaning shoe
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
JPH10262688A (ja) * 1994-11-30 1998-10-06 Univ Rockefeller 体重のモジュレーター、対応する核酸およびタンパク質、ならびにそれらの診断および治療用途
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ATE244574T1 (de) 1996-03-22 2003-07-15 Curis Inc Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
US6696557B1 (en) * 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
PE99498A1 (es) * 1996-07-26 1999-01-21 Novartis Ag Polipeptidos de fusion
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
PT2045322E (pt) * 1997-07-14 2015-10-16 Université de Liège Musculatura dupla em mamíferos
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB2345397B (en) * 1997-08-19 2001-10-31 Citizen Watch Co Ltd Piezoelectric vibrator
US6372454B2 (en) 1997-08-29 2002-04-16 Human Genome Sciences, Inc. Nucleic acid molecules encoding Follistatin-3
AU1276399A (en) * 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11
WO1999024618A1 (en) 1997-11-10 1999-05-20 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
AU2586199A (en) 1998-02-05 1999-08-23 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
DE69941116D1 (de) 1998-05-06 2009-08-27 Metamorphix Inc G von gdf-8
WO2000011163A1 (en) * 1998-08-20 2000-03-02 Regeneron Pharmaceuticals, Inc. Dcr5, a bmp-binding protein, and applications thereof
JP2003517580A (ja) * 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
WO2000073337A1 (en) * 1999-06-01 2000-12-07 Biogen, Inc. Polymer conjugates of hedgehog proteins and uses
AU778470B2 (en) 1999-07-20 2004-12-09 Pharmexa A/S Method for down-regulating GDF-8 activity
AU2001241817A1 (en) 2000-02-29 2001-09-12 Zymogenetics Inc. Kunitz domain polypeptide zkun8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL350983A1 (en) * 2001-11-30 2003-06-02 Advanced Digital Broadcast Ltd Method of scanning a high-frequency signal band and apparatus therefor
KR20040096592A (ko) 2002-02-21 2004-11-16 와이어쓰 폴리스타틴 도메인을 포함하는 단백질
MXPA04008150A (es) 2002-02-21 2005-06-17 Wyeth Corp Gasp1: una proteina que contiene dominio de folistatina.
US20040138118A1 (en) 2002-09-16 2004-07-15 Neil Wolfman Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7511012B2 (en) 2002-12-20 2009-03-31 Amgen Inc. Myostatin binding agents
CA2526669A1 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
MX2007011400A (es) 2005-03-23 2007-10-11 Wyeth Corp Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
US20060240488A1 (en) 2005-03-23 2006-10-26 Nowak John A Detection of an immune response to GDF-8 modulating agents

Also Published As

Publication number Publication date
TWI329129B (en) 2010-08-21
JP2006001938A (ja) 2006-01-05
ES2284828T3 (es) 2007-11-16
NO20033456L (no) 2003-10-06
DK1397492T3 (da) 2007-07-09
NZ527286A (en) 2006-11-30
US20070238683A1 (en) 2007-10-11
ATE357519T1 (de) 2007-04-15
US7202210B2 (en) 2007-04-10
JP4280071B2 (ja) 2009-06-17
WO2002068650B1 (en) 2004-01-08
US20030104406A1 (en) 2003-06-05
AR032567A1 (es) 2003-11-12
CA2674673A1 (en) 2002-09-06
NZ550297A (en) 2008-04-30
MXPA03007063A (es) 2004-10-15
JP2009091366A (ja) 2009-04-30
ZA200306064B (en) 2006-02-22
US20120252884A1 (en) 2012-10-04
BR0207110A (pt) 2005-08-16
SG187989A1 (en) 2013-03-28
WO2002068650A3 (en) 2003-08-21
US20100305194A1 (en) 2010-12-02
NO333427B1 (no) 2013-06-03
CA2437218A1 (en) 2002-09-06
US7737116B2 (en) 2010-06-15
JP5013618B2 (ja) 2012-08-29
EP1397492A2 (en) 2004-03-17
DE60219006T2 (de) 2007-12-13
US7560441B2 (en) 2009-07-14
TW200526779A (en) 2005-08-16
WO2002068650A2 (en) 2002-09-06
PL207202B1 (pl) 2010-11-30
HK1062457A1 (en) 2004-11-05
SG165982A1 (en) 2010-11-29
CL2009000648A1 (es) 2009-06-12
PL212078B1 (pl) 2012-08-31
PL372888A1 (en) 2005-08-08
CY1106629T1 (el) 2012-01-25
JP2005507637A (ja) 2005-03-24
DE60219006D1 (de) 2007-05-03
PT1397492E (pt) 2007-06-15
US8222384B2 (en) 2012-07-17
US20070149455A1 (en) 2007-06-28
NO20033456D0 (no) 2003-08-04
AU2002243852B2 (en) 2007-08-16
US8710025B2 (en) 2014-04-29
EP1397492B1 (en) 2007-03-21
US20140228289A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
EP1397492B1 (en) Modified and stabilized gdf propeptides and uses thereof
AU2002243852A1 (en) Modified and stabilized GDF propeptides and uses thereof
EP1572961B1 (en) Actriib fusion polypeptides and uses therefor
JP2020158546A (ja) 筋ジストロフィー治療のためのユートロフィン誘導に関するactriibタンパク質およびその改変体およびその使用
JP2005531505A (ja) フォリスタチン(follistatin)ドメイン含有タンパク質
EP1790726B1 (en) Modified and stabilized GDF propeptides and uses thereof